仙灵骨葆胶囊联合密固达治疗绝经后骨质疏松症26例临床观察  

Clinical Observation of 26 Cases of Postmenopausal Osteoporosis Treated with Xianlinggubao Capsule and Aclasta

作　　者：刘海全[1] 

机构地区：[1]广州中医药大学附属骨伤科医院,广州510240

出　　处：《北方药学》2015年第7期11-12,共2页Journal of North Pharmacy

基　　金：国家自然科学基金资助项目(项目编号:30901915)

摘　　要：目的:探讨仙灵骨葆胶囊联合密固达治疗绝经后骨质疏松症的临床效果。方法:选择符合临床观察要求病例26例,口服仙灵骨葆胶囊、静脉滴注密固达,同时配合口服钙制剂治疗。观察治疗后6个月、12个月的腰背部疼痛、骨密度改善情况及药物不良反应情况。结果:参照视觉模拟量表法,治疗后6个月、12个月,腰背部疼痛症状明显缓解;与治疗前比较具有显著性差异(P<0.05)。治疗6个月骨密度有所增加,但与治疗前比较没有显著性差异(P>0.05);治疗12个月后患者骨密度值明显增加,与治疗前比较有显著性差异(P<0.01)。结论:应用仙灵骨葆胶囊联合密固达治疗绝经后骨质疏松症,可以取得满意的临床疗效。Objective： To investigate the clinical effects of postmenopausal osteoporosis with the Xianlinggubao capsule and Aclasta. Methods： 26 cases were treated with oral Xianlinggubao capsule and intravenous infusion of Aclasta. Degree of pain, BMD and drug reactions were observed after 6 and12 months’ treatment. Result According to VAS, the pain on back were relieved after 6 and 12 months’ treatment. There was a significant difference compared with that of prior treatment （P〈0.05）. BMD increased after 6 months’ treatment, which was no significant difference compared with that of prior treatment （P〉0.05）. BMD increased significantly after 12 months’ treatment. There was significant difference compared with that of prior treatment （P〈0.01）. Conclusion Treatment of postmenopausal osteoporosis with Xianlinggubao capsule and Aclasta can achieve a satisfactory clinical outcome.

关 键 词：仙灵骨葆 密固达 骨质疏松症 临床观察 

分 类 号：R681.1[医药卫生—骨科学]